Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary C McElroy

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Inhalation Toxicology|March 14, 2013
Inhaled biopharmaceutical drug development: nonclinical considerations and case studiesMary C McElroy, Chris Kirton, Dan Gliddon, et al.
Pharmaceuticals (Basel, Switzerland)|January 25, 2025
Two- and Three-Dimensional Culture Systems: Respiratory In Vitro Tissue Models for Chemical Screening and Risk-Based Decision MakingJoanne Wallace, Mary C McElroy, Mitchell Klausner, et al.
Infection and Immunity|June 18, 2002
Increased virulence of a fibronectin-binding protein mutant of Staphylococcus aureus in a rat model of pneumoniaMary C McElroy, David J Cain, Christine Tyrrell, et al.
Experimental Lung Research|May 9, 2012
Differential alveolar epithelial injury and protein expression in pneumococcal pneumoniaChristine Tyrrell, Stuart R McKechnie, Michael F Beers, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 26, 2005
Coexpression of RTI40 with alveolar epithelial type II cell proteins in lungs following injury: identification of alveolar intermediate cell typesGareth R Clegg, Christine Tyrrell, Stuart R McKechnie, et al.
Pulmonary Pharmacology & Therapeutics|August 26, 2020
Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosisMark W Surber, Steve Beck, Stephen Pham, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Inhalation Toxicology|March 14, 2013
Inhaled biopharmaceutical drug development: nonclinical considerations and case studiesMary C McElroy, Chris Kirton, Dan Gliddon, et al.
Pharmaceuticals (Basel, Switzerland)|January 25, 2025
Two- and Three-Dimensional Culture Systems: Respiratory In Vitro Tissue Models for Chemical Screening and Risk-Based Decision MakingJoanne Wallace, Mary C McElroy, Mitchell Klausner, et al.
Infection and Immunity|June 18, 2002
Increased virulence of a fibronectin-binding protein mutant of Staphylococcus aureus in a rat model of pneumoniaMary C McElroy, David J Cain, Christine Tyrrell, et al.
Experimental Lung Research|May 9, 2012
Differential alveolar epithelial injury and protein expression in pneumococcal pneumoniaChristine Tyrrell, Stuart R McKechnie, Michael F Beers, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 26, 2005
Coexpression of RTI40 with alveolar epithelial type II cell proteins in lungs following injury: identification of alveolar intermediate cell typesGareth R Clegg, Christine Tyrrell, Stuart R McKechnie, et al.
Pulmonary Pharmacology & Therapeutics|August 26, 2020
Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosisMark W Surber, Steve Beck, Stephen Pham, et al.
Pageof 1